Form 4: Oncocyte Corp Director Patrick W. Smith Increases Stake Through Trust
SEC Form 4
Patrick W. Smith, a director of Oncocyte Corp, has increased his beneficial ownership through purchases of common stock via an irrevocable trust.
Summary
- On January 29, 2025, Patrick W. Smith, a director of Oncocyte Corp, acquired 3,880 shares of common stock at a price of $2.01 per share.
- On January 30, 2025, Smith acquired an additional 318 shares of common stock at $2.01 per share.
- These shares are held indirectly through The Smith Irrevocable Trust, for which Smith serves as trustee.
- Following these transactions, Smith's total indirect beneficial ownership amounts to 1,794,156 shares.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock purchases by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about insider trading activity.
Industry Context
This Form 4 filing is a routine disclosure of insider trading activity. It provides transparency into the actions of company directors and their investment decisions regarding the company's stock.
Stakeholder Impact
- Shareholders may view the director's stock purchases as a positive signal, indicating confidence in the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| 05/01/2015 | Date of The Smith Irrevocable Trust U/A |
| 01/29/2025 | Purchase of 3,880 shares of common stock at $2.01 |
| 01/30/2025 | Purchase of 318 shares of common stock at $2.01 |
| 01/31/2025 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.